Aug31Fri
Six Irish men to share $635m after sale of drug firm
Irish Times Business
Adapt Pharma’s Narcan spray used in the front line of opioid crisis in United States
Six Irish businessmen will share a $635 million (€542m) payday after selling a company that developed a drug used in the frontline as the United States battles an opioid crisis.
Waterford entrepreneur Seamus Mulligan and his team invested €115 million to set up Adapt Pharma just over four years ago. Their team focused on a drug, Naloxone, that has been in use for many years and is commonly used in hospital anaesthesia.
To read more, please click HERE.
Welcome to new members, Pendulum Summit, a Dublin-based company founded by Irish Rugby star Frankie Sheahan. Pendulum is the world’s leading business and self-empowerment summit.
Through Pendulum new membership in the Irish Chamber, we are delighted to offer all IABCN members a special discount on tickets to Pendulum Summit New York on September 13th at the PlayStation Theater in Times Square. This is a highly anticipated one day event that brings together hundreds of senior-level decision makers from across all industries to learn from and be inspired by some of the world’s most renowned figures from business and self-empowerment.
Offering a unique blend of ideas and inspiration, Pendulum Summit focuses on the issues most relevant to today’s business people, stimulating new thinking and motivating action. As the world’s leading business and self-empowerment summit, transforming the lives of 16,000+ attendees through its previous five sell out summits in Ireland, Pendulum Summit has chosen New York as part of its global mission.
ICON Reports Second Quarter 2018 Results
Highlights
• Excluding the impact of ASC 606, record net business wins in the quarter of $600 million; a book to bill of 1.27.
• Excluding the impact of ASC 606, closing backlog of $5.2 billion, an increase of 16% year on year.
• Quarter 2 reported revenue of $641.6 million. Excluding the impact of ASC 606, quarter 2 revenue was $473.9 million, representing a 10% increase year on year.
• Reported income from operations before non-recurring charges was $94.4 million, or 14.7% of revenue. Excluding the impact of ASC 606 income from operations before non-recurring charges was $96.0 million or 20.2% of revenue, a 12% increase year on year.
• Reported earnings per share before non-recurring charges of $1.51. Year to date earnings per share before non-recurring charges of $2.93, an increase of 13% on 2017. Excluding the impact of ASC 606, earnings per share before non-recurring items was $1.54, an 18% increase year on year.
• Revenue guidance increased from a range of $2,520 – $2,640 million to a range of $2,560 – $2,640 million. Earnings guidance increased from a range of $5.91 – $6.11 to a range of $5.98 – $6.12.
Jul25Wed
Almac Clinical Technologies Releases New Podcast Series Entitled “Spotlight on IRT: Best Practices”
Souderton, PA – 25 July 2018 – Almac Clinical Technologies, a global leader in technology-enabled solutions for managing clinical trial patient and supplies data through its flagship IXRS® 3 Interactive Response Technology (IRT) debuts a first-in-industry podcast series entitled, “Spotlight on IRT: Best Practices.”
Jul25Wed
Almac Group Appoints Three Vice Presidents
|
Craigavon, N.I., 25 July 2018 – Almac Group, the global contract development and manufacturing organisation, has announced the appointment of three new Vice Presidents within its Pharma Services Business Unit as it expands its executive team.
|
